PALI vs. FNCH, FRTX, TCON, NSTGQ, KRBP, TTNP, ALBT, ELOX, CHRO, and CELZ
Should you be buying Palisade Bio stock or one of its competitors? The main competitors of Palisade Bio include Finch Therapeutics Group (FNCH), Fresh Tracks Therapeutics (FRTX), TRACON Pharmaceuticals (TCON), NanoString Technologies (NSTGQ), Kiromic BioPharma (KRBP), Titan Pharmaceuticals (TTNP), Avalon GloboCare (ALBT), Eloxx Pharmaceuticals (ELOX), Chromocell Therapeutics (CHRO), and Creative Medical Technology (CELZ). These companies are all part of the "biological products, except diagnostic" industry.
Finch Therapeutics Group (NASDAQ:FNCH) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.
Finch Therapeutics Group's return on equity of -89.68% beat Palisade Bio's return on equity.
21.8% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by company insiders. Comparatively, 2.2% of Palisade Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Finch Therapeutics Group has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, Palisade Bio has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.
Finch Therapeutics Group received 3 more outperform votes than Palisade Bio when rated by MarketBeat users. Likewise, 52.63% of users gave Finch Therapeutics Group an outperform vote while only 41.18% of users gave Palisade Bio an outperform vote.
Palisade Bio has a consensus price target of $131.25, suggesting a potential upside of 2,023.79%. Given Finch Therapeutics Group's higher possible upside, analysts clearly believe Palisade Bio is more favorable than Finch Therapeutics Group.
Palisade Bio has higher revenue and earnings than Finch Therapeutics Group. Palisade Bio is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.
In the previous week, Palisade Bio had 6 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 8 mentions for Palisade Bio and 2 mentions for Finch Therapeutics Group. Palisade Bio's average media sentiment score of 0.67 beat Finch Therapeutics Group's score of 0.11 indicating that Finch Therapeutics Group is being referred to more favorably in the media.
Summary
Finch Therapeutics Group and Palisade Bio tied by winning 8 of the 16 factors compared between the two stocks.
Get Palisade Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PALI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Palisade Bio Competitors List
Related Companies and Tools
